ZTS Stock Overview
Engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Innovative Veterinary Solutions Fueling Market Expansion And Profit Growth
Zoetis Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$191.36 |
| 52 Week High | US$201.92 |
| 52 Week Low | US$144.80 |
| Beta | 0.88 |
| 11 Month Change | 3.30% |
| 3 Month Change | 8.82% |
| 1 Year Change | 1.95% |
| 33 Year Change | -5.99% |
| 5 Year Change | 56.31% |
| Change since IPO | 517.09% |
Recent News & Updates
There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price
Aug 30
Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target
Aug 13Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
Aug 07Recent updates
There's Reason For Concern Over Zoetis Inc.'s (NYSE:ZTS) Price
Aug 30Zoetis: Librela Sales Should Peak 200-300% Above Management's $1B Target
Aug 13Zoetis Q2 Earnings: Harvesting From DTC (Rating Upgrade)
Aug 07Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Jul 16Zoetis: A High-Quality Business And Fast Dividend Growth At A Reasonable Price
Jul 03Zoetis: Don't Fret Excessively Over The Animal Healthcare Leader
Jun 11A Look At The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Jun 10Zoetis (NYSE:ZTS) Ticks All The Boxes When It Comes To Earnings Growth
May 23Zoetis: Why The Focus On Companion Animal Segment Will Pay Off
May 22The Zoetis Inc. (NYSE:ZTS) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 04Zoetis: Long-Term Buy Despite Safety Concerns
May 03Despite Lawsuit Risks: Why Zoetis Remains A Compelling Investment
Apr 15Zoetis Inc.'s (NYSE:ZTS) Shareholders Might Be Looking For Exit
Apr 12Zoetis: My Favorite Healthcare Stock Right Now
Mar 21Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Mar 03Zoetis: Buy This High-Quality Dividend Growth Beast On Weakness
Feb 27Animal Kingdom's Ally: Zoetis And Its Path To 10%+ Returns
Jan 10Some Confidence Is Lacking In Zoetis Inc.'s (NYSE:ZTS) P/E
Jan 01Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Does Zoetis (NYSE:ZTS) Have A Healthy Balance Sheet?
Dec 06Here's Why We Think Zoetis (NYSE:ZTS) Might Deserve Your Attention Today
Nov 18Zoetis: High-Quality Compounder With A Reasonable Price After Earnings
Nov 09Zoetis: Significant CapEx Investments For Long-Term Growth, But A Hold Now
Oct 26Zoetis Is An Impressive Healthcare Compounder
Sep 26Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Sep 25Here's Why Zoetis (NYSE:ZTS) Can Manage Its Debt Responsibly
Sep 04Zoetis: Pawses Pain, Librela OA Treatment Targets Furry Friends In The U.S.
Aug 22Should You Be Adding Zoetis (NYSE:ZTS) To Your Watchlist Today?
Aug 12Zoetis: My Dog Approves Of This Dividend Compounder
Jul 19Zoetis: A Purrfect Addition To Your Portfolio
Jun 22Does This Valuation Of Zoetis Inc. (NYSE:ZTS) Imply Investors Are Overpaying?
Jun 10These 4 Measures Indicate That Zoetis (NYSE:ZTS) Is Using Debt Reasonably Well
Apr 16Estimating The Intrinsic Value Of Zoetis Inc. (NYSE:ZTS)
Mar 10Zoetis rises on 2023 revenue forecast above estimates, Q4 profit in-line with consensus
Feb 14Zoetis Is An Awesome Dividend Growth Stock
Jan 17It's A Great Time To Buy Zoetis Shares
Jan 10Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Jan 03Is Zoetis (NYSE:ZTS) Using Too Much Debt?
Dec 29Zoetis' (NYSE:ZTS) Upcoming Dividend Will Be Larger Than Last Year's
Dec 14Zoetis raises quarterly dividend by 15.4% to $0.375/share
Dec 08Estimating The Fair Value Of Zoetis Inc. (NYSE:ZTS)
Nov 20Zoetis' Q3 Earnings: Supply Issues Putting A Dent On Growth
Nov 08Shareholder Returns
| ZTS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.2% | -2.3% | -0.8% |
| 1Y | 1.9% | 15.4% | 20.5% |
Return vs Industry: ZTS underperformed the US Pharmaceuticals industry which returned 15.4% over the past year.
Return vs Market: ZTS underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| ZTS volatility | |
|---|---|
| ZTS Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ZTS has not had significant price volatility in the past 3 months.
Volatility Over Time: ZTS's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 14,100 | Kristin Peck | www.zoetis.com |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives.
Zoetis Inc. Fundamentals Summary
| ZTS fundamental statistics | |
|---|---|
| Market cap | US$86.86b |
| Earnings (TTM) | US$2.34b |
| Revenue (TTM) | US$8.92b |
37.0x
P/E Ratio9.7x
P/S RatioIs ZTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZTS income statement (TTM) | |
|---|---|
| Revenue | US$8.92b |
| Cost of Revenue | US$2.67b |
| Gross Profit | US$6.24b |
| Other Expenses | US$3.90b |
| Earnings | US$2.34b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.17 |
| Gross Margin | 70.01% |
| Net Profit Margin | 26.29% |
| Debt/Equity Ratio | 132.9% |
How did ZTS perform over the long term?
See historical performance and comparison